CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015)
CytomX Therapeutics' (CTMX) quarterly Non-Current Debt came in at $78000.0 in Q4 2015, down 95.03% YoY from $1.6 million in Q4 2014, and down 95.03% on a QoQ basis from $1.6 million in Q4 2014.
Powered by 
Analysis
CytomX Therapeutics (CTMX) Non-Current Debt (2014 - 2015) Analysis & Trends
CytomX Therapeutics (CTMX) has 2 years of Non-Current Debt data on file, last reported at $78000.0 in Q4 2015.
- Quarterly Non-Current Debt fell 95.03% year-over-year to $78000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $78000.0 (down 95.03% YoY) and the FY2015 annual result came in at $78000.0, down 95.03% from the prior year.
- Non-Current Debt fell to $78000.0 in Q4 2015, from $1.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.6 million in Q4 2014 to a low of $78000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 546.77 Mn |
| 10 | CytomX Therapeutics | 793.66 Mn | 463.38 Mn | - | - |